Notice: This company recently went public with an IPO on Friday, October 11th 2024. They issued 12,500,000 shares at $15.00-$17.00 per share. We will continue to update data for UPB as it becomes available.

Upstream Bio (UPB) Competitors

$23.60

-0.03 (-0.13%)

(As of 10/17/2024 ET)

Compare

UPB vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROW

Should you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry.

Upstream Bio vs.

Upstream Bio (NASDAQ:UPB) and 180 Life Sciences (NASDAQ:ATNFW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership.

: In the previous week, Upstream Bio had 4 more articles in the media than 180 Life Sciences. MarketBeat recorded 4 mentions for Upstream Bio and 0 mentions for 180 Life Sciences. Upstream Bio's average media sentiment score of 0.75 beat 180 Life Sciences' score of 0.00 indicating that Upstream Bio is being referred to more favorably in the media.
Company Overall Sentiment
Upstream Bio Positive
180 Life Sciences Neutral
: Upstream Bio and 180 Life Sciences both received 0 outperform votes by MarketBeat users.
Company Underperform Outperform
Upstream Bio N/A N/A
180 Life Sciences N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Upstream Bio $2.22M N/A N/A N/A N/A
180 Life Sciences N/A N/A N/A N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Upstream Bio
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
180 Life Sciences
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Company Net Margins Return on Equity Return on Assets
Upstream Bio N/A N/A N/A
180 Life Sciences N/A N/A N/A

Company	Overall Sentiment
Upstream Bio	Positive
180 Life Sciences	Neutral

Company	Underperform	Outperform
Upstream Bio	N/A	N/A
180 Life Sciences	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.22M	N/A	N/A	N/A	N/A
180 Life Sciences	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
180 Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	N/A	N/A	N/A
180 Life Sciences	N/A	N/A	N/A

Summary

Upstream Bio beats 180 Life Sciences on 3 of the 3 factors compared between the two stocks.

Ad Crypto 101 Media

DeFi Coin on Verge of Breakout!

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Get Upstream Bio News Delivered to You Automatically

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPB vs. The Competition

Export to Excel

Metric	Upstream Bio	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$3.67B	$5.43B	$8.49B
Dividend Yield	N/A	3.33%	4.64%	4.11%
P/E Ratio	N/A	300.94	140.95	19.25
Price / Sales	N/A	9,164.18	1,194.16	89.56
Price / Cash	N/A	13.68	38.22	33.61
Price / Book	N/A	6.47	4.86	4.66
Net Income	N/A	$57.26M	$119.00M	$227.46M
7 Day Performance	N/A	8.99%	3.36%	3.34%
1 Month Performance	N/A	31.97%	16.49%	11.68%
1 Year Performance	N/A	25.25%	32.67%	27.61%

Upstream Bio Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	Employee Count	Indicator(s)
UPB Upstream Bio	N/A	$23.60 -0.1%	N/A	N/A	$0.00	$2.22M	38	Insider Buying
ATNFW 180 Life Sciences	N/A	$0.01 flat	N/A	+38.2%	$0.00	N/A	7	Positive News Gap Down High Trading Volume
SXTPW 60 Degrees Pharmaceuticals	N/A	$0.04 flat	N/A	-75.7%	$0.00	$418,304.00	2	Positive News
DRTSW Alpha Tau Medical	N/A	$0.18 flat	N/A	N/A	$0.00	N/A	80	Gap Up
WENAW Anew Medical	N/A	$0.04 -0.3%	N/A	N/A	$0.00	N/A	N/A	Gap Down
APLMW Apollomics	N/A	$0.01 flat	N/A	-80.0%	$0.00	N/A	59	Gap Up
BCTXW BriaCell Therapeutics	N/A	$0.30 -9.1%	N/A	-82.6%	$0.00	N/A	8	Gap Down
CDIOW Cardio Diagnostics	N/A	$0.04 flat	N/A	N/A	$0.00	$39,138.00	7	Gap Down
CTCXW Carmell	N/A	$0.09 -19.0%	N/A	-52.8%	$0.00	$12,320.00	9	Positive News
CELUW Celularity	N/A	$0.01 flat	N/A	-30.8%	$0.00	$22.77M	220	Positive News Gap Down
CEROW CERo Therapeutics	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	8	Gap Up